Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

ICON Launches New Medical Imaging Solution for Early Phase Trials

Published: Thursday, October 25, 2012
Last Updated: Thursday, October 25, 2012
Bookmark and Share
Streamlined early phase offering designed to support faster decision making.

ICON plc, has announced the launch of a new medical imaging solution tailored to the unique requirements of early phase trials.

This new solution incorporates streamlined processes and procedures to maximize the information collected from image data and to ensure that this information is processed rapidly in line with the shorter timelines and requirements of early-phase research.

Enhanced decision making is then enabled by MIRA™, ICON’s image management system, which standardizes data from all imaging formats and allows for centralized analysis and interpretation of data.

Driving this innovation is a team of scientific and regulatory experts with deep imaging and early-phase experience to help sponsors make critical decisions about their compounds faster.

“PET, volumetrics, advanced CT and MRI are increasingly being used in early phase research which has created a demand for more tailored imaging solutions for early phase trials,” commented Ted Gastineau, President, ICON Medical Imaging.

Gastineau continued, “We have developed a unique and cost-effective solution that provides true insight to the data generated from imaging technologies and helps clients decide earlier about the future success of a drug.”

ICON Medical Imaging’s early phase group will be led by Dr. James Conklin, Senior Vice President, Medical and Scientific Affairs and Dr. Valerie Treyer, Director, Medical and Scientific Affairs, who together bring over 45 years of experience in the management of medical image data used in clinical trials.

The group will work closely with ICON Development Solutions which provides a full range of early-phase services, including clinical pharmacology, bioanalytical, PK/PD modelling and simulation, and Clinical Pharmacodynamic Models for early indications of drug efficacy.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ICON to Acquire ClinicalRM
The acquisition will enhance ICON’s ability to access the market for government sponsored research and further enhances its capabilities in the areas of vaccines and infectious disease.
Friday, July 08, 2016
ICON Acquires PMG Research Inc.
Acquisition enhances ICON’s site and patient engagement capabilities.
Tuesday, December 15, 2015
ICON Partners with iCardiac Technologies
ICON certified as a partner of iCardiac’s early precision QT® program.
Saturday, November 07, 2015
ICON Creates New Global Innovation Hub in Ireland
Global Innovation Hub will create 200 Scientific, IT and Business jobs in Ireland.
Thursday, February 05, 2015
ICON Selected by the FDA to Develop New PRO Measure for HABP Trials
New PRO measure being developed in conjunction with the FNIH Biomarkers Consortium.
Thursday, November 13, 2014
ICON Launches New Analytics Service for Advanced Medical Review of Laboratory Data
ICONIK Labs allows visualization, analysis and reporting on laboratory data in real time.
Tuesday, November 19, 2013
ICON Announces Appointment to Board of Directors
ICON plc today announced the appointment of Professor William Hall as a non-executive director.
Friday, February 22, 2013
ICON to Acquire Clinical Trial Services Division of Cross Country Healthcare Inc
Acquisition expands ICON’s global resourcing, FSP and safety capabilities.
Thursday, February 07, 2013
ICON Selected by Shire as Global Strategic Partner
Global strategic partner for clinical research and central laboratory services.
Monday, January 23, 2012
Scientific News
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Anti-Inflammatory Drugs Could Help Treat Depression
Anti-inflammatory drugs could be used to treat some cases of depression, which further implicates our immune system in mental health disorders.
NIH Contributes to Global Effort to Prevent and Manage Lung Diseases
The large scale trial will measure health benefits of clean cookstoves.
Questioning the Safety of Selenium to Combat Cancer
Research indicates the need for change in practice as selenium supplements cannot be recommended for preventing colorectal cancer.
Scientists at NIH and Emory Achieve Sustained SIV Remission in Monkeys
The finding suggest that the immune systems of these animals are controlling SIV replication in the absence of antiretroviral therapy.
Painting the Way to Tumour Imaging
Tumour paint used in emergency surgery to aid cell identification for surgeons.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
Targeting Estrogen Receptor Improves Survival in Breast Cancer
Trial finds estrogen receptor degrader significantly increases progression-free survival in patients with advanced breast cancer.
Clinical Trial Finds Medicine Program Alters Blood Serum
Meditation, yoga and vegetarian diet linked to decline in plasma metabolites associated with inflammation and cardiovascular disease risk.
Alzheimer’s Linked Protein Can Be Removed From Brain Without Hindering Memory, Learning
Researchers at UTSW have found that the mice can maintain their learning and memory when virtually all ApoE is removed from the brain but kept present in the liver to filter cholesterol.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos